Humanized Anti-GPC-1 Antibody for High-Affinity Cell Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of a humanized anti-Glypican-1 monoclonal antibody with high affinity and internalization activity for GPC-1-positive cells, limiting effective therapeutic applications for Glypican-1-positive cancers.
Innovation Solution
Development of a humanized anti-GPC-1 monoclonal antibody with high affinity and internalization activity, usable in therapeutic applications and companion diagnostic reagents for Glypican-1-positive cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a mouse anti-GPC-1 antibody is used, then high affinity and internalization activity are achieved, but humanization is required for clinical application
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's species origin from mouse to human through humanization processes. This involves changing the immunological parameters (species specificity) while maintaining the functional parameters (affinity and internalization activity) through careful selection and optimization of humanized antibody variants.
2Ease of manufacture
If no humanized anti-GPC-1 antibody is used, then development complexity is reduced, but therapeutic application effectiveness is limited
Solution Approach 1:
The patent applies preliminary action by conducting extensive preclinical research and characterization of the humanized anti-GPC-1 antibody before clinical application. This includes preliminary studies on affinity, internalization activity, and therapeutic potential in preclinical models, which justifies the development complexity and ensures therapeutic effectiveness before human use.
3Adaptability or versatility
If a humanized anti-GPC-1 antibody is developed, then therapeutic applications are enabled, but development time and resources are increased
Solution Approach 1:
The patent applies copying by utilizing the successful mouse anti-GPC-1 antibody as a template or blueprint for creating the humanized version. The mouse antibody's proven affinity and internalization activity serve as a model, allowing the humanized antibody to be developed by transferring these functional characteristics to a human immune system context, thereby reducing development time compared to de novo development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The humanized anti-Glypican-1 antibody is effective for diagnosis and targeted treatment of Glypican-1-positive cancers, with a complex of the antibody and a cytotoxic medicine showing high efficacy in cancer treatment.
Implementation Method 1
a humanized anti-GPC-1 monoclonal antibody that has high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells
Implementation Method 2
a humanized anti-GPC-1 monoclonal antibody that has high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.